Translate page


Saglio EHA 2019 CML Treatment in the Era of Operational Cure: Considerations for Therapy Selection
Professor Giuseppe Saglio, University of Turin, Italy
  • Clinical case: Women, 39 years old including;
    • Considerations for prognosis
    • Considerations on the possibility of TFR
  • ENESTnd study - 5 year update including cumulative incidence of MR4.5
  • Nilotinib is the only TKI registered for discontinuation
  • Summary of Steering Group recommendations derived from patient-physician discussion
  • Conclusion 

This talk was first presented at EHA during the Satellite Symposium: 'Optimizing patient outcomes in CML and classical MPN's: New treatment paradigms and future developments' - supported by Incyte. You will find more education materials from EHA at the EHA Learning Centre